Increased interleukin-17A levels promote rituximab resistance by suppressing p53 expression and predict an unfavorable prognosis in patients with diffuse large B cell lymphoma

Rituximab resistance has become increasingly common in patients with diffuse large B cell lymphoma (DLBCL). However, the mechanisms involved remain unclear. In this study, we aimed to examine the effect of rituximab on interleukin (IL)-17A and to investigate the role of IL-17A in rituximab resistanc...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Int J Oncol
Asıl Yazarlar: Zhong, Weijie, Xu, Xin, Zhu, Zhigang, Yang, Li, Du, Hong, Xia, Zhongjun, Yuan, Zhaohu, Xiong, Huabao, Du, Qinghua, Wei, Yaming, Li, Qingshan
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: D.A. Spandidos 2018
Konular:
Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5873833/
https://ncbi.nlm.nih.gov/pubmed/29512700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ijo.2018.4299
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller